Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Thrombosis and Thrombolysis
Published in: Journal of Thrombosis and Thrombolysis 4/2016

01-05-2016

Acute and long-term effect of percutaneous coronary intervention on serially-measured oxidative, inflammatory, and coagulation biomarkers in patients with stable angina

Authors: Gregor Leibundgut, Jun-Hee Lee, Bradley H. Strauss, Amit Segev, Sotirios Tsimikas

Published in: Journal of Thrombosis and Thrombolysis | Issue 4/2016

Login to get access

Abstract

To derive insights into the temporal changes in oxidative, inflammatory and coagulation biomarkers in patients with stable angina undergoing percutaneous coronary intervention (PCI). PCI is associated with a variety of biochemical and mechanical stresses to the vessel wall. Oxidized phospholipids are present on plasminogen (OxPL-PLG) and potentiate fibrinolysis in vitro. We recently showed that OxPL-PLG increase following acute myocardial infarction, suggesting that they are involved in atherothrombosis. Plasma samples were collected before, immediately after, 6 and 24 h, 3 and 7 days, and 1, 3, and 6 months after PCI in 125 patients with stable angina undergoing uncomplicated PCI. Plasminogen levels, OxPL-PLG, and an array of 16 oxidative, inflammatory and coagulation biomarkers were measured with established assays. OxPL-PLG and plasminogen declined significantly immediately post-PCI, rebounded to baseline, peaked at 3 days and slowly returned to baseline by 6 months (p < 0.0001 by ANOVA). The temporal trends to maximal peak in biomarkers were as follows: immediately post PCI: OxPL-apoB and lipoprotein (a); Day 1—the inflammatory biomarker IL-6; Day 3—CRP and coagulation biomarkers OxPL-PLG, plasminogen and tissue plasminogen activity; Day 3 to 7—plasminogen activator inhibitor activity, and complement factor H binding to malondialdehyde-LDL and MDA-LDL IgG; Day 7–30 MDA-LDL IgM, CuOxLDL IgM, and ApoB-IC IgM and IgG; >30 days uPA activity, uPA antigen, CuOxLDL IgG and peptide mimotope to MDA-LDL. Most of the biomarkers trended to baseline by 6 months. PCI results in a specific, temporal sequence of changes in plasma biomarkers. These observations provide insights into the effects of iatrogenic barotrauma and plaque disruption during PCI and suggest avenues of investigation to explain complications of PCI and development of targeted therapies to enhance procedural success.
Appendix
Available only for authorised users
Literature
1.
Prati F, Pawlowski T, Gil R, Labellarte A, Gziut A, Caradonna E et al (2003) Stenting of culprit lesions in unstable angina leads to a marked reduction in plaque burden: a major role of plaque embolization? A serial intravascular ultrasound study. Circulation. 107(18):2320–2325CrossRefPubMed
2.
Ravandi A, Leibundgut G, Hung M-Y, Patel M, Hutchins PM, Murphy RC et al (2014) Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans. J Am Coll Cardiol 21(63):1961–1971CrossRef
3.
Juni RP, Duckers HJ, Vanhoutte PM, Virmani R, Moens AL (2013) Oxidative stress and pathological changes after coronary artery interventions. J Am Coll Cardiol 61(14):1471–1481CrossRefPubMed
4.
Breuss JM, Cejna M, Bergmeister H, Kadl A, Baumgartl G, Steurer S et al (2002) Activation of nuclear factor-κB significantly contributes to lumen loss in a rabbit iliac artery balloon angioplasty model. Circulation 105(5):633–638CrossRefPubMed
5.
van Dijk RA, Kolodgie F, Ravandi A, Leibundgut G, Hu PP, Prasad A et al (2012) Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res 53(12):2773–2790CrossRefPubMedPubMedCentral
6.
Choi S-H, Yin H, Ravandi A, Armando A, Dumlao D, Kim J et al (2013) Polyoxygenated cholesterol ester hydroperoxide activates TLR4 and SYK dependent signaling in macrophages. PLoS One 8(12):e83145CrossRefPubMedPubMedCentral
7.
Tsimikas S, Lau HK, Han K-R, Shortal B, Miller ER, Segev A et al (2004) Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation 109(25):3164–3170CrossRefPubMed
8.
Fefer P, Tsimikas S, Segev A, Sparkes J, Otsuma F, Kolodgie F et al (2012) The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization. Cardiovasc Revasc Med. 13(1):11–19CrossRefPubMed
9.
Segev A, Strauss BH, Witztum JL, Lau HK, Tsimikas S (2005) Relationship of a comprehensive panel of plasma oxidized low-density lipoprotein markers to angiographic restenosis in patients undergoing percutaneous coronary intervention for stable angina. Am Heart J 150(5):1007–1014CrossRefPubMed
10.
Tsimikas S, Kiechl S, Willeit J, Mayr M, Miller ER, Kronenberg F et al (2006) Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J Am Coll Cardiol 47(11):2219–2228CrossRefPubMed
11.
Leibundgut G, Arai K, Orsoni A, Yin H, Scipione C, Miller ER et al (2012) Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction. J Am Coll Cardiol. 59(16):1426–1437CrossRefPubMedPubMedCentral
12.
Strauss BH, Lau HK, Bowman KA, Sparkes J, Chisholm RJ, Garvey MB et al (1999) Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. Circulation 100(15):1616–1622CrossRefPubMed
13.
Taleb A, Witztum JL, Tsimikas S (2011) Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomark Med 5(5):673–694CrossRefPubMedPubMedCentral
14.
Bertoia ML, Pai JK, Lee J-H, Taleb A, Joosten MM, Mittleman MA et al (2013) Oxidation-specific biomarkers and risk of peripheral artery disease. J Am Coll Cardiol 61(21):2169–2179CrossRefPubMedPubMedCentral
15.
Capoulade R, Chan KL, Yeang C, Mathieu P, Bossé Y, Dumesnil JG et al (2015) Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis. J Am Coll Cardiol 66(11):1236–1246CrossRefPubMed
16.
Byun YS, Lee J-H, Arsenault BJ, Yang X, Bao W, DeMicco D et al (2015) Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J Am Coll Cardiol 65(13):1286–1295CrossRefPubMed
17.
Weismann D, Hartvigsen K, Lauer N, Bennett KL, Scholl HPN, Charbel Issa P et al (2011) Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 478(7367):76–81CrossRefPubMed
18.
19.
Tsimikas S, Mallat Z, Talmud PJ, Kastelein JJP, Wareham NJ, Sandhu MS et al (2010) Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol 56(12):946–955CrossRefPubMed
20.
Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F et al (2007) Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol 27(8):1788–1795CrossRefPubMed
21.
Rodenburg J, Vissers MN, Wiegman A, Miller ER, Ridker PM, Witztum JL et al (2006) Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J Am Coll Cardiol 47(9):1803–1810CrossRefPubMed
22.
Amir S, Hartvigsen K, Gonen A, Leibundgut G, Que X, Jensen-Jarolim E et al (2012) Peptide mimotopes of malondialdehyde epitopes for clinical applications in cardiovascular disease. J Lipid Res 53(7):1316–1326CrossRefPubMedPubMedCentral
23.
Segev A, Kassam S, Buller CE, Lau HK, Sparkes JD, Connelly PW et al (2004) Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary angiographic restenosis after elective stenting. Eur Heart J 25(12):1029–1035CrossRefPubMed
24.
Tsimikas S, Bergmark C, Beyer RW, Patel R, Pattison J, Miller E et al (2003) Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 41(3):360–370CrossRefPubMed
25.
Heusch G, Kleinbongard P, Böse D, Levkau B, Haude M, Schulz R et al (2009) Coronary microembolization: from bedside to bench and back to bedside. Circulation 120(18):1822–1836CrossRefPubMed
26.
Sato H, Iida H, Tanaka A, Tanaka H, Shimodouzono S, Uchida E et al (2004) The decrease of plaque volume during percutaneous coronary intervention has a negative impact on coronary flow in acute myocardial infarction: a major role of percutaneous coronary intervention-induced embolization. J Am Coll Cardiol 44(2):300–304CrossRefPubMed
27.
Leineweber K, Böse D, Vogelsang M, Haude M, Erbel R, Heusch G (2006) Intense vasoconstriction in response to aspirate from stented saphenous vein aortocoronary bypass grafts. J Am Coll Cardiol 47(5):981–986CrossRefPubMed
28.
Hojo Y, Ikeda U, Katsuki T, Mizuno O, Fukazawa H, Kurosaki K et al (2000) Release of endothelin 1 and angiotensin II induced by percutaneous transluminal coronary angioplasty. Catheter Cardiovasc Interv 51(1):42–49CrossRefPubMed
29.
Schachinger V, Halle M, Minners J, Berg A, Zeiher AM (1997) Lipoprotein(a) selectively impairs receptor-mediated endothelial vasodilator function of the human coronary circulation. J Am Coll Cardiol 30(4):927–934CrossRefPubMed
30.
Gallimore MJ, Aasen AO, Erichsen NS, Larsbraaten M, Lyngaas K, Amundsen E (1980) Plasminogen concentrations and functional activities and concentrations of plasmin inhibitors in plasma samples from normal subjects and patients with septic shock. Thromb Res 18(5):601–608CrossRefPubMed
31.
Donoso LA, Vrabec T, Kuivaniemi H (2010) The role of complement factor H in age-related macular degeneration: a review. Surv Ophthalmol 55(3):227–246CrossRefPubMed
32.
Koeijvoets KCMC, Mooijaart SP, Dallinga-Thie GM, Defesche JC, Steyerberg EW, Westendorp RGJ et al (2009) Complement factor H Y402H decreases cardiovascular disease risk in patients with familial hypercholesterolaemia. Eur Heart J 30(5):618–623CrossRefPubMed
33.
Sofat R, Casas JP, Kumari M, Talmud PJ, Ireland H, Kivimaki M et al (2010) Genetic variation in complement factor H and risk of coronary heart disease: eight new studies and a meta-analysis of around 48,000 individuals. Atherosclerosis. 213(1):184–190CrossRefPubMed
34.
Pai JK, Manson JE, Rexrode KM, Albert CM, Hunter DJ, Rimm EB (2007) Complement factor H (Y402H) polymorphism and risk of coronary heart disease in US men and women. Eur Heart J 28(11):1297–1303CrossRefPubMed
35.
Meng W, Hughes A, Patterson CC, Belton C, Kamaruddin MS, Horan PG et al (2007) Genetic variants of complement factor H gene are not associated with premature coronary heart disease: a family-based study in the Irish population. BMC Med Genet 8:62CrossRefPubMedPubMedCentral
36.
Iltumur K, Karabulut A, Toprak G, Toprak N (2005) Complement activation in acute coronary syndromes. APMIS. 113(3):167–174CrossRefPubMed
37.
Ferluga J, Kishore U, Sim RB (2014) A potential anti-coagulant role of complement factor H. Mol Immunol 59(2):188–193CrossRefPubMed
38.
Ramharack R, Barkalow D, Spahr MA (1998) Dominant negative effect of TGF-beta1 and TNF-alpha on basal and IL-6-induced lipoprotein(a) and apolipoprotein(a) mRNA expression in primary monkey hepatocyte cultures. Arterioscler Thromb Vasc Biol 18(6):984–990CrossRefPubMed
39.
DeFilippis AP, Chernyavskiy I, Amraotkar AR, Trainor PJ, Kothari S, Ismail I et al (2015) Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction. J Thromb Thrombolysis. 2015:1–6
40.
Leibundgut G, Witztum JL, Tsimikas S (2013) Oxidation-specific epitopes and immunological responses: translational biotheranostic implications for atherosclerosis. Curr Opin Pharmacol. 2013:1–12
41.
Tsimikas S, Willeit P, Willeit J, Santer P, Mayr M, Xu Q et al (2012) Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J Am Coll Cardiol 60(21):2218–2229CrossRefPubMed
42.
Tsimikas S, Duff GW, Berger PB, Rogus J, Huttner K, Clopton P et al (2014) Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). J Am Coll Cardiol 63(17):1724–1734CrossRefPubMedPubMedCentral
43.
Briley-Saebo K, Yeang C, Witztum JL, Tsimikas S (2014) Imaging of oxidation-specific epitopes with targeted nanoparticles to detect high-risk atherosclerotic lesions: progress and future directions. J Cardiovasc Transl Res. 7(8):719–736CrossRefPubMedPubMedCentral
44.
Binder CJ, Horkko S, Dewan A, Chang M-K, Kieu EP, Goodyear CS et al (2003) Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 9(6):736–743CrossRefPubMed
45.
Tsimikas S, Miyanohara A, Hartvigsen K, Merki E, Shaw PX, Chou M-Y et al (2011) Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression. J Am Coll Cardiol 58(16):1715–1727CrossRefPubMedPubMedCentral
46.
Fang L, Green SR, Baek JS, Lee S-H, Ellett F, Deer E et al (2011) In vivo visualization and attenuation of oxidized lipid accumulation in hypercholesterolemic zebrafish. J Clin Invest. 121(12):4861–4869CrossRefPubMedPubMedCentral
Metadata
Title
Acute and long-term effect of percutaneous coronary intervention on serially-measured oxidative, inflammatory, and coagulation biomarkers in patients with stable angina
Authors
Gregor Leibundgut
Jun-Hee Lee
Bradley H. Strauss
Amit Segev
Sotirios Tsimikas
Publication date
01-05-2016
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 4/2016
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-016-1351-6

Other articles of this Issue 4/2016

Journal of Thrombosis and Thrombolysis 4/2016 Go to the issue

OriginalPaper

Combination of rosuvastatin and probucol inhibits MMP-9 expression via upregulation of miR-497 in cultured HUVECs and apoE knockout mice

OriginalPaper

Simplified PESI score and sex difference in prognosis of acute pulmonary embolism: a brief report from a real life study

OriginalPaper

Investigation of adverse effects of interactions between herbal drugs and natural blood clotting mechanism

Report

An entrapped in flagranti thrombus

OriginalPaper

The impact of schistosomes and schistosomiasis on murine blood coagulation and fibrinolysis as determined by thromboelastography (TEG)

OriginalPaper

Risk factors for pulmonary embolism in patients preliminarily diagnosed with community-acquired pneumonia: a prospective cohort study
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits